Hester Biosciences Ltd (HESTERBIO) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- The company experienced a mixed performance in the first half of FY26, characterized by a weaker India business but stronger consolidated profitability, which was supported by improved cost controls and operational stability.
- The standalone business saw a decline in top-line performance, primarily due to delays in government-led immunization programs for PPR and Lumpy Skin Disease, which management views as a timing issue rather than a lack of demand.
- The Poultry Healthcare division demonstrated robust growth, driven by strong, volume-led demand for its core vaccine portfolio, signaling underlying strength in this segment.
- A significant regulatory milestone was achieved with the market authorization for the H9N2 (avian influenza) vaccine, which is expected to strengthen the poultry portfolio and unlock new export opportunities.
- The company is focused on strengthening its business fundamentals by reducing dependency on tender-based revenues and deepening its presence in commercial, private, and export markets to build a more resilient and balanced portfolio.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.